Suven gets European patent for SUVN-502

Font Size

Print

Feedback

Email

Discuss

Save & Share Article

What’s this?

Digg	My Yahoo	Fark
del.icio.us	Newsvine	Reddit

Rate This Article

Mumbai, May 5: Pharmaceutical firm Suven Life Sciences on Monday said it has received European product patent for its clinical candidate SUVN-502, valid until June 2023.

European Patent Office granted the product patent – EP 1581492 -- which is an exclusive intellectual property (IP) of Suven and was achieved through the internal discovery research efforts, the company said in a filing to the Bombay Stock Exchange.

"We are very pleased by the grant of this patent for our clinical candidate SUVN-502 which is being developed for Central Nervous System (CNS) disorders," Suven Life Sciences CEO Venkat Jasti said.

The said drug candidate is being developed for treatment of neuro-generative disorders like Alzheimer's disease, attention deficit hyperactivity disorder, memory impairment associated with ageing and Schizophrenia.

Potential market opportunity for these indications is more than 18 billion dollars globally.

With EP 1581492, Suven has four European Product Patents granted and all of them have been validated in all the 37 member countries of Europe including major Markets like Germany, Switzerland, Denmark, Spain, France, The United Kingdom, Italy, Netherlands, Poland, Sweden and Finland.